Abstracts tagged "gout"

Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Robert Terkeltaub¹, JuneSik Mune², Jieun Lee³ and Kenneth Saag⁴, ¹VA/UCSD, San Diego, CA, ²LG Chem, Ltd., Seoul, ³LG Chem, Ltd., Seoul, South Korea, ⁴The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
Abstract Number: 0467 • ACR Convergence 2021
Assessing the Extent of Lumbosacral Spinal Urate Deposition in Patients with Tophaceous and Nontophaceous Gout Compared with Non-gout Controls Using Dual-Energy CT (DECT)
Michael Toprover¹, Michael Mechlin¹, Anastasia Slobodnick¹, Virginia Pike¹, Cheongeun Oh¹, Claudine Davis¹, Theodore Fields², Fabio Becce³ and Michael Pillinger⁴, ¹NYU Langone Health, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴New York University Grossman School of Medicine, New York,, NY
Background/Purpose: Axial gout involvement was first reported in 1950 (1). Over 100 cases have subsequently been published. Reported cases have presented as acute back pain,…
Abstract Number: 0675 • ACR Convergence 2021
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Anushree Tiku¹, Neil Boudville², Fiona Brown³, Alan Cass⁴, Phiilip Clarke⁵, Richard Day⁶, Janak de Zoysa⁷, Bettina Douglas⁸, Randall Faull⁹, David Harris¹⁰, Carmel Hawley¹¹, Graham Jones⁶, John Kanellis³, Elaine Pascoe¹¹, Suetonia Palmer¹², Vlado Perkovic¹³, Gopala Rangan¹⁰, Donna Reidlinger¹¹, Laura Robison¹¹, Robert Walker¹⁴, Giles Walters¹⁵, David Johnson¹¹, Sunil Badve¹³ and Nicola Dalbeth⁷, ¹The George Institute of Australia, Sydney, Australia, ²University of Western Australia, Perth, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies School of Health Research, Darwin, Australia, ⁵University of Oxford, Oxford, United Kingdom, ⁶University of New South Wales, Sydney, Australia, ⁷University of Auckland, Auckland, New Zealand, ⁸Princess Alexandra Hospital, Brisbane, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰University of Sydney, Sydney, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²University of Otago, Christchurch, New Zealand, ¹³The George Institute for Global Health, Sydney, Australia, ¹⁴University of Otago, Dunedin, New Zealand, ¹⁵The Canberra Hospital, Canberra, Australia
Background/Purpose: The CKD-FIX randomized controlled trial showed that allopurinol did not slow decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with…
Abstract Number: 1567 • ACR Convergence 2021
Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients
Luigi Brunetti¹, Lujing Wang², Andrew Wassef², Anita Brinker³, Brian T Buckley⁴, Peter Lipsky⁵, Ah-Ng Kong² and Naomi Schlesinger⁶, ¹Rutgers The State University of New Jersey, Piscataway, NJ, ²Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, ³Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey,, Piscataway, NJ, ⁴Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, ⁵AMPEL BioSolutions, Charlottesville, VA, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Tart cherries (TC) contain high levels of anthocyanins that exert potent antioxidant and anti-inflammatory effects. Approximately 50% of gout patients report using TC to…
Abstract Number: 0578 • ACR Convergence 2021
Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and the metabolic (insulin resistance) syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate (SU) levels in physiologic studies1 and…
Abstract Number: 0676 • ACR Convergence 2021
Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
Lesley Jackson¹, Narender Annapureddy², Kenneth Saag¹, James Booth³, Giovanna Rosas¹, Jeffrey Foster¹, Amy Mudano¹, Dongmei Sun⁴, John Osborne¹, Tim Bongartz⁵, Erik Hess⁵, Colleen Lawrence⁶, Leah Dunkel⁶ and Maria I. Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University Medical Center, Nashville, TN, ³Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁶Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with acute gout are frequently treated in emergency departments (ED) and represent a typically underserved and understudied population. A key limitation of conducting…
Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
zancong shen¹, Elizabeth Polvent², vijay hingorani³, Rongzi Yan⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc., San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Vanguard Healthsciences, Inc., San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…
Abstract Number: 0660 • ACR Convergence 2021
Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
Kazuki Yoshida, Tianrun Cai, Lily G. Bessette, Erin Kim, Su Been Lee, Luke E. Zabotka, Alec Sun, Jun Liu, DH Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recurrent gout flares are the most crucial outcome in studies of gout treatment. However, gout flares is challenging to identify in a large population…
Abstract Number: 0677 • ACR Convergence 2021
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Globally, the prevalence of gout is rising in females more than males,1 but data on modifiable risk factors for female gout are scarce. Emerging…
Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Christopher Podgorski¹, Paula Skarda² and Elie Gertner³, ¹Department of Medicine, University of Minnesota Medical School, Saint Paul, MN, ²Department of Medicine, Regions Hospital, University of Minnesota Medical School, Saint Paul, MN, ³Section of Rheumatology, Regions Hospital and Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…
Abstract Number: 0661 • ACR Convergence 2021
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Lisa Stamp¹, Rebecca Grainger², Chris Frampton¹, Jill Drake¹ and Catherine Hill³, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Wellington, New Zealand, ³Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), also known as omega-3 fats act as alternate COX substrates to arachidonic acid (AA). Their metabolism results…
Abstract Number: 0678 • ACR Convergence 2021
Is There a Difference in Self-reported Flare Frequency Between Men and Women?
Naomi Schlesinger¹, Nicholas A Sumpter², Nicola Dalbeth³, Lisa Stamp⁴ and Tony Merriman⁵, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: There is increasing recognition of gout among women. The postmenopausal rise in serum urate levels in women increases the risk for the development of…
Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Bilal Bengana¹, Aicha Ladjouze², Nabil Baramtane Raaf³, Chaffa Aimeur⁴, Soraya Ayoub⁵, Abdenour Boukabous⁶ and Salima Lefkir-Tafiani⁷, ¹University Hospital of Beni Messous Algiers - Rheumatology Department, Algiers, Algeria, ²Specialized hospital establishment of Benaknoune, Rheumatology, Algiers, Algeria, ³Hospital of Bitraria, Biochemistry, El Biar, Algiers, Algeria, ⁴University hospital of Mustapha Bacha, Radiology, Sidi Mhamed, Algiers, Algeria, ⁵University hospital of Beni Messous, Internal Medicine, BeniMessous, Algiers, Algeria, ⁶University Hospital of Beni Messous Algiers- Rheumatology Department, Algiers, Algeria, ⁷University Hospital of Beni Messous Algiers - Rheumatology Department, Benimessous, Algeria
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…
Abstract Number: 0662 • ACR Convergence 2021
Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials
Lisa Stamp¹, Chris Frampton¹, Melanie Morillon², William Taylor³, Nicola Dalbeth⁴, Jasvinder Singh⁵, Micheal Doherty⁶, Weiya Zhang⁶, Helen Richardson⁶, Aliya Sarmanova⁷ and Robin Christensen⁸, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²Odense University Hospital, Odense, Denmark, ³University of Otago, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nottingham, Nottingham, United Kingdom, ⁷University of Bristol Medical School, Bristol, United Kingdom, ⁸Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark
Background/Purpose: Use of serum urate (SU) as a treatment target and outcome measure has become controversial in light of the American College of Physician Gout…

1
2
3
…
32
Next Page »